| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441500 | European Journal of Cancer | 2016 | 7 Pages |
Abstract
While fostamatinib was generally well tolerated in this patient population, efficacy at these doses and schedule was poor. Unlike data with other B-cell antigen receptor pathway inhibitors, responses were not observed in the ABC genotype.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ian W. Flinn, Nancy L. Bartlett, Kristie A. Blum, Kirit M. Ardeshna, Ann S. LaCasce, Christopher R. Flowers, Andrei R. Shustov, Kenneth S. Thress, Patrick Mitchell, Fred Zheng, Jeffrey M. Skolnik, Jonathan W. Friedberg,